PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Forst, T.* ; de Block, C.* ; Del Prato, S.* ; Armani, S.* ; Frias, J.* ; Lautenbach, A.* ; Ludvik, B.* ; Marinez, M.* ; Mathieu, C.* ; Müller, T.D. ; Schnell, O.*

The role of incretin receptor agonists in the treatment of obesity.

Diabetes Obes. Metab., DOI: 10.1111/dom.15796 (2024)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
INTRODRODUCTION: Obesity and its associated metabolic conditions have become a significant global health problem in recent years, with many people living with obesity fulfilling criteria for pharmacological treatment. The development of the glucagon-like peptide-1 receptor agonists for chronic weight management has triggered new interest in the incretins and other hormones as targets for obesity, and investigations into dual and triple co-agonists. METHODS: The objective of this narrative review was to summarize the available data on approved and emerging incretin-based agents for the treatment of obesity. RESULTS: In clinical trials of currently available agents in people with overweight or obesity, weight loss of between 6% and 21% of baseline body weight has been observed, with between 23% and 94% of participants achieving 10% or higher weight loss, depending on the study and the agent used. Favourable outcomes have also been seen with regard to cardiovascular risk and outcomes, diabetes prevention, metabolic dysfunction-associated steatotic liver disease/steatohepatitis and prevention of weight regain after metabolic surgery. Limitations associated with these agents include high costs, the potential for weight regain once treatment is stopped, the potential loss of lean body mass and gastrointestinal adverse events; potential issues with respect to gallbladder and biliary diseases require further investigation. CONCLUSIONS: Many dual and triple co-agonists are still in development, and more data are needed to assess the efficacy, safety and tolerability of these emerging therapies versus the established incretin-based therapies; however, data are promising, and further results are eagerly awaited.
Impact Factor
Scopus SNIP
Altmetric
5.400
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Dual Co‐agonists ; Incretins ; Obesity ; Semaglutide ; Tirzepatide; Glucagon-like Peptide-1; Semaglutide 2.4 Mg; Weekly Subcutaneous Semaglutide; Once-weekly Cagrilintide; Double-blind; Weight-loss; Body-weight; Glycemic Control; Food-intake; Nonalcoholic Steatohepatitis
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 1462-8902
e-ISSN 1463-1326
Zeitschrift Diabetes, Obesity and Metabolism
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
Förderungen Clinical Research Services, Grenadiesrstrasse 1, 68167 Mannheim, Germany
DOI 10.1111/dom.15796
WOS ID 001278728600001
Scopus ID 85199972602
PubMed ID 39072877
Erfassungsdatum 2024-08-01
[➜Korrektur melden]